10% OFF Crypto | 3rd Party Tested | FREE Worldwide Shipping $400+ ($750+ for USA)
Menu
Cart
tesamorelin with ipamorelin 10/3 mg blend lyophilized peptide vial
edge peptides tesamorelin ipamorelin 5 mg blend chromate test
lyophilized peptide vial box (white cap)

Tesamorelin + Ipamorelin Blend 10/3mg – 10 Vial Box

$540.0

Cost per vial $: 54

Buy tesamorelin + ipamorelin blend 10/3 mg (one 10-vial box). All orders are shipped wholesale in unbranded packaging. Worldwide 7 – 14 day shipping to the USA, UK, AUS & NZ.

Bulk discounts
Quantity Bulk Discount Price
210%$486.0
3-515%$459.0
6-1020%$432.0
SKU: TESIPA5 Categories: ,

Description

Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). It works by stimulating the pituitary gland to produce and release more growth hormone (GH). Ipamorelin is another peptide that tells the body to produce and release more growth hormone by mimicking the action of the natural peptide ghrelin.

Combining the two can lead to synergistic effects on growth hormone because they work through different mechanisms.

Minimum order quantity: one box (10 vials x 10/3 mg, 100 mg tesa/30 mg ipa in total).

Note: Product images show branded labels for illustration purposes only. All peptides are shipped in wholesale, unbranded packaging. You can see an actual example photo of the peptide vials and container above.

Additional information

Purity

≥99.0%
Cost per vial $

54
  1. Wang, Ying, and Brian Tomlinson. "Tesamorelin, a human growth hormone releasing factor analogue." Expert Opinion on Investigational Drugs 18.3 (2009): 303-310.
  2. Grunfeld, Carl, Argyris Dritselis, and Peter Kirkpatrick. "Tesamorelin." Nature Reviews Drug Discovery 10.2 (2011): 95-97.
  3. Clemmons, David R., Sam Miller, and Jean-Claude Mamputu. "Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial." PLoS One 12.6 (2017): e0179538.
  4. Falutz, Julian, et al. "Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation." Aids 22.14 (2008): 1719-1728.
  5. Stanley, Takara L., et al. "Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial." The Lancet HIV 6.12 (2019): e821-e830.
  6. Falutz, Julian, et al. "Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data." The Journal of Clinical Endocrinology & Metabolism 95.9 (2010): 4291-4304.
  7. Stanley, Takara L., et al. "Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial." Jama 312.4 (2014): 380-389.
  8. Spooner, Linda M., and Jacqueline L. Olin. "Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy." Annals of Pharmacotherapy 46.2 (2012): 240-247.
  9. Raun, Kirsten, et al. "Ipamorelin, the first selective growth hormone secretagogue." European journal of endocrinology 139.5 (1998): 552-561.
  10. Andersen, N. B., et al. "The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats." Growth Hormone & IGF Research 11.5 (2001): 266-272.
  11. Beck, David E., et al. "Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients." International journal of colorectal disease 29 (2014): 1527-1534.
  12. Gobburu, Jogarao VS, et al. "Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers." Pharmaceutical research 16 (1999): 1412-1416.

Tesamorelin + Ipamorelin Blend Chromate Test (May 2025)

Related products